Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8521291 | 0.94 | DNM1 (0.34) | CA1CA12CA9CA2CES2 | |
| SCHEMBL3500621 | 0.86 | — | — | |
| SCHEMBL103667 | 0.80 | CA12 (0.40) | CA1CA12CA9MMP1MMP2 | |
| SCHEMBL103820 | 0.78 | CA12 (0.39) | CA1CA12CA9MMP1MMP2 | |
| SCHEMBL103877 | 0.77 | ALDH1A1 (0.40) | CA1CA12CA9MMP1MMP2 | |
| SCHEMBL1168252 | 0.77 | — | — | |
| Ethyl Nitrosourea SCHEMBL77485 | 0.77 | — | — | |
| SCHEMBL29441478 | 0.76 | MEN1 (0.31) | CA1CA12CA9MEN1KMT2A | |
| SCHEMBL31462921 | 0.74 | CA12 (0.35) | CA1CA12CA9MMP1MMP2 | |
| SCHEMBL11179593 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104031047-A | Novel chloroethyl nitrosourea with anticancer activity and synthesizing method thereof | UNIV BEIJING TECHNOLOGY | 2014-09-10 | — | — | CN | claimed |
| WO-2024097746-A1 | ALKENE CYCLOPROPANATION WITH NICKEL CATALYST ENHANCER AND IMPROVED REARRANGEMENT REACTION | CONAGEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3060535-B1 | PROCESS FOR THE CYCLOPROPANATION OF OLEFINS USING N-ALKYL-N-NITROSO COMPOUNDS | GIVAUDAN SA (CH) | 2020-08-05 | — | — | EP | disclosed |
| CN-105658604-B | Among organic compound or it is related to the improvement of organic compound | 奇华顿股份有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-105503874-B | Hypoxemia activates joint chloroethylnitrosoureas compound and preparation method and application | 北京工业大学 | 2017-10-27 | — | — | CN | disclosed |
| US-20170283342-A1 | ORGANIC COMPOUNDS | Givaudan, S.A. (CH) | 2017-10-05 | — | — | US | disclosed |
| US-9718741-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3060535-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-31 | — | — | EP | disclosed |
| CN-104031047-B | A kind of chlorethylnitrosourea and synthetic method thereof with antitumour activity | BEIJING UNIVERSITY OF TECHNOLOGY (CN) | 2016-03-09 | — | — | CN | disclosed |
| WO-2015059290-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-30 | — | — | WO | disclosed |
| CN-104031047-A | Novel chloroethyl nitrosourea with anticancer activity and synthesizing method thereof | UNIV BEIJING TECHNOLOGY | 2014-09-10 | — | — | CN | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-1999011701-A1 | METHODS OF USING A BUTYLUREA GEL COMPOSITION FOR THE TREATMENT AND PREVENTION OF INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSITY (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5602284-A | TREATING DIPHENYLAMINE WITH DOUBLE-BONDED OXYGEN COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283342-A1 | ORGANIC COMPOUNDS | NOC2L, NOS2, NCL | CA1 2373/4885CA12 482/4885CA9 1205/4885 |
| US-20160280615-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOC2L, NPM1, NOS2 | CA1 2207/4885CA12 443/4885CA9 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.